Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherBrief Communication

Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Copper-67

Lachlan E. McInnes, Carleen Cullinane, Peter Roselt, Susan Jackson, Benjamin Blyth, Ellen van Dam, Nicholas A. Zia, Matthew J. Harris, Rodney J. Hicks and Paul S. Donnelly
Journal of Nuclear Medicine October 2020, jnumed.120.251579; DOI: https://doi.org/10.2967/jnumed.120.251579
Lachlan E. McInnes
1 School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carleen Cullinane
2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Roselt
3 Cancer Imaging, Peter MacCallum Cancer Centre;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Jackson
2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Blyth
2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen van Dam
4 Clarity Pharmaceuticals Ltd., Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas A. Zia
1 School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Harris
4 Clarity Pharmaceuticals Ltd., Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney J. Hicks
2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul S. Donnelly
1 School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising treatment for prostate cancer. We reported a ligand featuring two lysine-ureido-glutamate groups, 64Cu-CuSarbisPSMA previously. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated following treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA I&T. Results: At 13 days post-injection, tumor growth was similarly inhibited by the two tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated administrations (2 x 15MBq, two weeks apart). Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.

  • Peptides
  • Radiochemistry
  • Radiopharmaceuticals
  • copper-64
  • copper-67
  • prostate cancer
  • prostate specific membrane antigen
  • theranostics
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Copper-67
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Copper-67
Lachlan E. McInnes, Carleen Cullinane, Peter Roselt, Susan Jackson, Benjamin Blyth, Ellen van Dam, Nicholas A. Zia, Matthew J. Harris, Rodney J. Hicks, Paul S. Donnelly
Journal of Nuclear Medicine Oct 2020, jnumed.120.251579; DOI: 10.2967/jnumed.120.251579

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Copper-67
Lachlan E. McInnes, Carleen Cullinane, Peter Roselt, Susan Jackson, Benjamin Blyth, Ellen van Dam, Nicholas A. Zia, Matthew J. Harris, Rodney J. Hicks, Paul S. Donnelly
Journal of Nuclear Medicine Oct 2020, jnumed.120.251579; DOI: 10.2967/jnumed.120.251579
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Brief Communication

  • Head to head comparison of 68Ga-NGUL and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study
  • Surgical feasibility, Determinants and overall Efficacy assessment of Neoadjuvant PRRT with 177Lu-DOTATATE for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
  • Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy
Show more Brief Communication

Basic (Radionuclide Therapy)

  • Comparative preclinical biodistribution, dosimetry and endoradiotherapy in mCRPC using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
  • Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
  • Preclinical evaluation of 213Bi-/225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer
Show more Basic (Radionuclide Therapy)

Similar Articles

Keywords

  • Peptides
  • radiochemistry
  • Radiopharmaceuticals
  • copper-64
  • copper-67
  • prostate cancer
  • prostate specific membrane antigen
  • theranostics
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire